Market Data 
Markets
Replies to post #2062 on Vitro Diagnostics Inc (fka VODG)
“We are testing almost 10 kind of mediums from different makers. The result is that your MSC-GroTM is most powerful candidate among them.”
Our current operational strategy involves expanding market penetration of our MSC research products together with development of products and services to support clinical applications of stem cells in treatment of animal and human conditions. Our MSC-Gro™ cell culture media is now available as Clinical Grade material for use in MSC expansion prior to transplantation. There are several clinical trials ongoing now using MSC-based treatments of a variety of conditions. These studies often require expansion of stem cells prior to transplantation. Our Clinical Grade MSC-Gro™ has numerous competitive advantages for use in this application. We have recently established bulk distribution of Clinical Grade MSC-Gro™ to an off-shore customer and we intend to expand this business considerably. We are also pursuing collaboration involving the use of select terminally differentiated cells developed by Vitro Biopharma for use in preclinical toxicology screening of drug candidates. Our cells targeting this market include MSC-derived cardiomyocytes, MSC-derived neurons including a-motorneurons and dopaminergic neurons together with Nephron Progenitor Cell (NPC)-derived PTECs (proximal tubule epithelial cells) & podocytes. Our NPCs are initially derived from MSCs prior to terminal differentiation into the functional cells of the kidney. Thus our products enable cell-based assays of cardiovascular, neural and kidney toxicity. When combined with hepatocytes, this provides an in-vitro ADMET screening process that not only determines direct drug toxicity but also allows determination of the toxicity of drug metabolites.
We are establishing clinical trials for the treatment of neurological conditions. This is supported by numerous studies suggesting stem cell efficacy in the treatment of stroke, ALS, and traumatic brain injury/concussion. We are nearing approval of our first US-based clinical trial for treatment of TBI/concussion and hope to begin patient recruitment during the summer of 2015. TBI affects 1.5 million people a year in the US only and lacks effective therapy, now relying predominantly on physical therapy/rehabilitation. Our trial will test novel diagnostics for recovery of brain function by the activation of stem cells residing within the brain.
We also have a proprietary cell line with application to treatment of skeletal muscular conditions in horses. This cell line has now advanced through all pre-clinical studies and we anticipate on-set of clinical trials of this cell line in late 2015. We are targeting tendonitis treatment as the primary indication. Tendonitis is common among sporting horses and often leads to discontinuation of racing or other competition during to lack of functional recovery. Stem cell therapy has been shown to result in functional recovery and resumption of competitive activities.
AI
